Psoriatic arthritis - etanercept and infliximab (TA104) (replaced by TA199)
Etanercept and infliximab for the treatment of psoriatic arthritis
This guidance has been replaced by TA199 Psoriatic arthritis - etanercept, infliximab and adalimumab
Please note that there is a minor discrepancy between the electronic version of the ‘quick reference guide’ (QRG) on the NICE website and the hard copy version that was mailed to the NHS to arrive on Wednesday 26 July. Section 1.3 of the guidance should read as follows:
1.3 Infliximab, within its licensed indications, is recommended for the treatment of adults with severe active psoriatic arthritis if, under the circumstances outlined in section 1.1, treatment with an anti-TNF (tumour necrosis factor) agent is considered appropriate and the person has been shown to be intolerant of, or have contraindications to, treatment with etanercept or has major difficulties with self administered injections.
The electronic version of the QRG that has been published on the NICE website is the correct version. A follow-up mailing to the NHS explaining this error and enclosing a hard copy of the correct version of the QRG will be sent out shortly.
- None found
This page was last updated: 20 December 2011
Implementation tools and resources
- None available
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.